258 related articles for article (PubMed ID: 28729405)
1. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.
McKeown MR; Corces MR; Eaton ML; Fiore C; Lee E; Lopez JT; Chen MW; Smith D; Chan SM; Koenig JL; Austgen K; Guenther MG; Orlando DA; Lovén J; Fritz CC; Majeti R
Cancer Discov; 2017 Oct; 7(10):1136-1153. PubMed ID: 28729405
[TBL] [Abstract][Full Text] [Related]
2. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
de Botton S; Cluzeau T; Vigil C; Cook RJ; Rousselot P; Rizzieri DA; Liesveld JL; Fenaux P; Braun T; Banos A; Jurcic JG; Sekeres MA; Savona MR; Roboz GJ; Bixby D; Madigan K; Volkert A; Stephens K; Kang-Fortner Q; Baker K; Paul S; McKeown M; Carulli J; Eaton M; Hodgson G; Fiore C; Kelly MJ; Roth DA; Stein EM
Blood Adv; 2023 May; 7(9):1858-1870. PubMed ID: 36477975
[TBL] [Abstract][Full Text] [Related]
3. Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia.
McKeown MR; Johannessen L; Lee E; Fiore C; di Tomaso E
Haematologica; 2019 Apr; 104(4):e138-e142. PubMed ID: 30337363
[No Abstract] [Full Text] [Related]
4. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW; Sias-Garcia O; Daramola A; Wei H; Terrell M; Rashid R; Park WD; Duong K; Horton TM; Li F; Cherayil N; Koren JV; Gant VU; Junco JJ; Curry CV; Stevens AM; Lin CY; Yi JS
Blood Adv; 2021 Dec; 5(23):4864-4876. PubMed ID: 34543389
[TBL] [Abstract][Full Text] [Related]
5. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with
Stein EM; de Botton S; Cluzeau T; Pigneux A; Liesveld JL; Cook RJ; Rousselot P; Rizzieri DA; Braun T; Roboz GJ; Lebon D; Heiblig M; Baker K; Volkert A; Paul S; Rajagopal N; Roth DA; Kelly M; Peterlin P
Leuk Lymphoma; 2023 Dec; 64(12):1992-2001. PubMed ID: 37571998
[TBL] [Abstract][Full Text] [Related]
6. Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
Fabiani E; Cicconi L; Nardozza AM; Cristiano A; Rossi M; Ottone T; Falconi G; Divona M; Testi AM; Annibali O; Castelli R; Lazarevic V; Rego E; Montesinos P; Esteve J; Venditti A; Della Porta M; Arcese W; Lo-Coco F; Voso MT
Cancer Med; 2021 Jun; 10(12):3839-3847. PubMed ID: 34042280
[TBL] [Abstract][Full Text] [Related]
7. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A; Bertran SP; Lu Y; Garcia A; Jones AM; Dawson MI; Farias EF
Breast Cancer Res; 2012 Aug; 14(4):R121. PubMed ID: 22920668
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.
Wang E; Aifantis I
Cancer Discov; 2017 Oct; 7(10):1065-1066. PubMed ID: 28974530
[TBL] [Abstract][Full Text] [Related]
9. p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.
Gianni M; Peviani M; Bruck N; Rambaldi A; Borleri G; Terao M; Kurosaki M; Paroni G; Rochette-Egly C; Garattini E
Leukemia; 2012 Aug; 26(8):1850-61. PubMed ID: 22354283
[TBL] [Abstract][Full Text] [Related]
10. BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.
Perri M; Yap JL; Yu J; Cione E; Fletcher S; Kane MA
Exp Cell Res; 2014 Oct; 327(2):183-91. PubMed ID: 25088254
[TBL] [Abstract][Full Text] [Related]
11. Recurrent
Osumi T; Tsujimoto SI; Tamura M; Uchiyama M; Nakabayashi K; Okamura K; Yoshida M; Tomizawa D; Watanabe A; Takahashi H; Hori T; Yamamoto S; Hamamoto K; Migita M; Ogata-Kawata H; Uchiyama T; Kizawa H; Ueno-Yokohata H; Shirai R; Seki M; Ohki K; Takita J; Inukai T; Ogawa S; Kitamura T; Matsumoto K; Hata K; Kiyokawa N; Goyama S; Kato M
Cancer Res; 2018 Aug; 78(16):4452-4458. PubMed ID: 29921692
[TBL] [Abstract][Full Text] [Related]
12. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
Benedetti L; Grignani F; Scicchitano BM; Jetten AM; Diverio D; Lo Coco F; Avvisati G; Gambacorti-Passerini C; Adamo S; Levin AA; Pelicci PG; Nervi C
Blood; 1996 Mar; 87(5):1939-50. PubMed ID: 8634442
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamics-Based Strategy of Using Retinoic Acid Receptor and Retinoid X Receptor Agonists to Induce MicroRNA-10a and Inhibit Atherosclerotic Lesion.
Lee DY; Chiu JJ
Methods Mol Biol; 2019; 2019():143-169. PubMed ID: 31359395
[TBL] [Abstract][Full Text] [Related]
14. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia.
Chim CS; Wong SY; Pang A; Chu P; Lau JS; Wong KF; Kwong YL
Leukemia; 2005 Dec; 19(12):2241-6. PubMed ID: 16239915
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
Sakamoto K; Imamura T; Yano M; Yoshida H; Fujiki A; Hirashima Y; Hosoi H
Blood Cancer J; 2014 Apr; 4(4):e205. PubMed ID: 24769646
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
[TBL] [Abstract][Full Text] [Related]
17. Co-occurrence of PML-RARA gene fusion, chromosome 8 trisomy, and FLT3 ITD mutation in a young female patient with de novo acute myeloid leukemia and early death: A CARE case report.
Tripon F; Crauciuc GA; Bogliş A; Moldovan V; Sándor-Kéri J; Benedek IJ; Trifa AP; Bănescu C
Medicine (Baltimore); 2020 Apr; 99(14):e19730. PubMed ID: 32243411
[TBL] [Abstract][Full Text] [Related]
18. A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene.
Yuan C; Zhang YS; Cheng YN; Xue X; Xu WF; Qu XJ
Leuk Lymphoma; 2012 Feb; 53(2):295-304. PubMed ID: 21846186
[TBL] [Abstract][Full Text] [Related]
19. AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid.
Classen CF; Teigler-Schlegel A; Röttgers S; Reinhardt D; Döhner K; Debatin KM
Ann Hematol; 2005 Nov; 84(12):774-80. PubMed ID: 16044313
[TBL] [Abstract][Full Text] [Related]
20. A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.
Tan Y; Wang X; Song H; Zhang Y; Zhang R; Li S; Jin W; Chen S; Fang H; Chen Z; Wang K
Blood; 2021 Mar; 137(11):1503-1516. PubMed ID: 32854112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
